Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy  by Wu, Yunzhou et al.
ble at ScienceDirect
Journal of Pharmacological Sciences 132 (2016) 24e30Contents lists availaJournal of Pharmacological Sciences
journal homepage: www.elsevier .com/locate/ jphsFull paperRecombinant Newcastle disease virus (NDV/Anh-IL-2) expressing
human IL-2 as a potential candidate for suppresses growth of
hepatoma therapy
Yunzhou Wu a, 1, Jinjiao He a, 1, Ying An a, Xi Wang d, Yunye Liu a, Shijun Yan a,
Xianlong Ye b, Jianying Qi b, Shenglong Zhu e, Qingzhong Yu c, Jiechao Yin a,
Deshan Li a, **, Wenfei Wang a, *
a College of Life Science, Northeast Agriculture University, Mucai Street 59, Xiangfang District, Harbin, PR China
b School of Life Science, Henan Normal University, 46 Jianshe Road E., Xinxiang, PR China
c Southeast Poultry Research Laboratory, Agricultural Research Service, United States Department of Agriculture, 934 College Station Road, Athens, GA
30605, USA
d Department of Stomach, Spleen and Portal Hypertension, The First Afﬁliated Hospital of Harbin Medical University, 23 Youzheng Str, Nangang District,
Harbin, PR China
e School of Food Science and Technology, State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, PR Chinaa r t i c l e i n f o
Article history:
Received 5 October 2015
Received in revised form
12 March 2016
Accepted 24 March 2016
Available online 27 April 2016
Keywords:
Newcastle disease virus
Oncolysis
Hepatoma
Hepatocellular carcinoma
IL-2* Corresponding author.
** Corresponding author.
E-mail addresses: deshangli@163.com (D. Li
(W. Wang).
Peer review under responsibility of Japanese Pha
1 Yunzhou Wu and Jinjiao He are co-ﬁrst authors.
http://dx.doi.org/10.1016/j.jphs.2016.03.012
1347-8613/© 2016 The Authors. Production and hostin
license (http://creativecommons.org/licenses/by-nc-na b s t r a c t
Newcastle disease virus (NDV) have shown oncolytic therapeutic efﬁcacy in preclinical study and are
currently approved for clinical trials. NDV Anhinga strain which is a mesogenic strain should be classiﬁed
as lytic strain and has a therapeutic efﬁcacy in hepatocellular cancer. In this study, we evaluated the
capacity of NDV Anhinga strain to elicit immune reaction in vivo and the possibility for using as a vaccine
vector for expressing tumor therapeutic factors. Interleukin-2 (IL-2) could boost the immune response
against the tumor cells. Therefore, we use NDV Anhinga strain as backbone to construct a recombinant
virus (NDV/Anh-IL-2) expressing IL-2. The virus growth curve showed that the production of recombi-
nant NDV/Anh-IL-2 was slightly delayed compared to the wild type. The NDV/Anh-IL-2 strain could
express soluble IL-2 and effectively inhibit the growth of hepatocellular carcinoma in vivo. 60 days post-
treatment, mice which were completely cured by previous treatment were well protected when
rechallenged with the same tumor cell. From the H&E-stained sections, intense inﬁltration of lympho-
cyte was observed in the NDV Anhinga strain treated group, especially in NDV/Anh-IL-2 group. The NDV
Anhinga strain could not only kill the tumor directly, but could also elicit immune reaction and a potent
immunological memory when killing tumor in vivo. In conclusion, the Anhinga strain could be an
effective vector for tumor therapy; the recombinant NDV/Anh-IL-2 strain expressing soluble IL-2 is a
promising candidate for hepatoma therapy.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).), wangwenfei@neau.edu.cn
rmacological Society.
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d/4.0/).1. Introduction
Oncolytic virus is a promising agent for cancer treatment,
employing nature's own agents to identify and destroy malignant
cells (1). Newcastle disease virus (NDV) is one of the naturally
occurring viruses with inherent oncolytic ability and potential for
cancer therapy (2e4). NDV is a single-strand non-segmented
negative-sense RNA virus belonging to the Paramyxoviridae family.
The genome contains 15186 nucleotides coding for six viral proteins
in the order 30-NP-P-M-F-HN-L-50 separated by non-transcribednese Pharmacological Society. This is an open access article under the CC BY-NC-ND
Fig. 1. Construction of the NDV/Anh-IL-2 virus. This picture displays the genome of
recombinant NDV/Anh-IL-2 virus. IL-2 gene fragment was inserted into the BstBI site
between HN and L genes of plasmid pAnh-wt. The gene-start and gene-end sequences
were introduced before the ORF of the IL-2 gene by PCR.
Y. Wu et al. / Journal of Pharmacological Sciences 132 (2016) 24e30 25intergenic (IG) sequences named gene-end (GE), IG and gene-start
(GS) (5). NDV causes severe illnesses in avian, but only mild ﬂu-like
symptoms in humans (6). The virus speciﬁcally replicates in cancer
cells rather than in normal cells because of the defective interferon
(IFN) signal pathways in cancer cells (2,3,7,8).
Direct mechanism and indirect mechanism mediated NDV-
mediated oncolysis (9). The direct oncolytic mechanism is
inducing apoptosis through mitochondrial apoptosis pathway
which require the viral entry, replication, de novo protein synthesis
and activation of caspases (10). The indirect oncolytic mechanism is
the immune mediated responses associated with both innate and
adaptive immune responses. After infection, NDV induced the
expression of immune cytokines (11), and then activated the
cytotoxic T-cell, macrophages, NK cells and monocytes for tumor
recognizing and tumor killing. But different NDV strains have
different effects on tumor therapy and suit for different tumor
lineages. Whether the NDV Anhinga strain could elicit a powerful
immune response and be a potent vaccine vector is still unknown.
Interleukin-2 (IL-2) has been demonstrated as a powerful drug
in clinical tumor therapy over 20 years, which can selectively
stimulate human T cells (12). The mature IL-2 consists of 133 amino
acids, with a molecular weight of 15.4 kDa. IL-2 are mainly secreted
by CD4þ and CD8þ T lymphocytes, it can stimulate proliferation,
cytolytic activity and cytokine secretion of T lymphocytes and
natural killer cells (13,14).
In the present study, we introduced NDV Anhinga strain as a
vaccine vector for expressing IL-2. We evaluated the efﬁciencies of
recombinant virus NDV/Anh-IL-2 for IL-2 expressing and in hepa-
tocellular carcinoma therapy. Our data demonstrated that soluble
IL-2 (sIL-2) could be secreted when virus replication. More over the
recombinant virus NDV/Anh-IL-2 could signiﬁcantly enhancing the
antitumor capability of NDV in vivo and induces more lymphocyte
inﬁltration than Anhinga wild strain suggesting that NDV Anhinga
strain could be used as a vaccine vector and recombinant virus
NDV/Anh-IL-2 is a promising candidate for cancer therapy.
2. Materials and methods
2.1. Cell lines and culture
HepG2 tumor cell was obtained from the China Xiehe Medical
University, H22 cell was kindly offered by Harbin Pharmaceutical
Group Bioengineering Co., LTD. BHK-21 cell was kindly offered by
Prof. Karl-Klaus Conzenlmann (Max-von-Pettenkofer Institut,
Muenchen). Chicken ﬁbroblast cell line DF-1, the human hepatoma
cell line HepG2 and the baby hamster kidney cell line BHK-21 were
grown in DMEM (GIBCO) with 10% heat-inactivated fetal bovine
serum (FBS), 100 mg mL1 streptomycin, 100 mg mL1 penicillin. All
cell lines were incubated at 37 C in an atmosphere of 5% CO2.
2.2. Plasmids and virus
The mesogenic NDV Anhinga strain was used to provide a
backbone for construction of the recombinant virus. The plasmids
pAnh-wt, pTM-N, pTM-P, pTM-Lwere kept in our lab and have been
described by Carlos et al (15,16). To generate the NDV Anhinga
strain expressing IL-2 [GenBank: NM_000586.3], the fragment of
IL-2 was cloned into BstBI site between the HN and L genes in
pAnh-wt. The recombinant plasmid encoding anti-genome of the
NDV Anhinga strain and IL-2 gene was named pAnh-IL-2. The re-
combinant NDV viruses were generated as previously described
(17) and sequenced by reverse transcription PCR for ﬁdelity. Re-
combinant virus NDV/Anh and NDV/Anh-IL-2 which express IL-2
were kept in our lab. The structure of the Recombinant viruses as
diagramed in Fig. 1.2.3. In vitro viral growth in HepG2 cell line
Viral growth was determined in the HepG2 cell line. Cells
planted in 24-well plates were infected with recombinant virus at
MOI of 10. The supernatants were collected at 24, 48, 72 and 96 h
post infection. The viral concentration was measured by end-point
titration on DF-1 cells and calculated as 50% tissue culture infective
dose (log10TCID50) per mL.2.4. Expression of IL-2 by tumor cells infected with NDV/Anh-IL-2
The expression levels of IL-2 gene in the supernatant of trans-
fected monolayers was measured by means of enzyme immune
assay as described by Human IL-2 Quantikine ELISA kit (R&D sys-
tems). Cells in six-well plates were infected with recombinant vi-
ruses NDV/Anh-IL-2 and NDV/Anh at multiplicities of infection
(MOI) of 10. The inoculums were removed 6 h post incubation. The
cells were photographed at 24, 48 and 72 h post infection. The
OD450 nm of the samples was determined and plotted against a
standard curve. The standard curve was generated by serially
diluting the stock enzyme IL-2 in dilution buffer supplied by the kit.2.5. Animal studies
All procedures involving animals followed the guidelines is-
sued by National Institute of Health and the Institutional Animal
Care and Use Committee of Northeast Agriculture University. Six-
week-old female Kunming mice were housed in a pathogen-free
environment and implanted subcutaneously with 5  105 H22
cells. Tumor volume was measured every other day using a digital
caliper in two dimensions. Tumor volumewas calculated using the
formula: V¼ 4/3 p S2/2 L/2, where V is the tumor volume, S is
the smaller measured diameter and L is the larger diameter (2).
When tumor size reached 5e8 mm in diameter (8e10 days), mice
were intratumorally injected with 107 pfu of NDV/Anh-IL-2
(200 ml) viruses every other day for a total of four injections,
phosphate buffered saline (PBS) (200 ml) and 107 pfu of NDV/Anh
(200 ml) as control. Animals were sacriﬁced when tumor size
reached 18 mm in any dimension or at the termination of the
experiment.
Fig. 2. Growth curve for recombinant NDV/Anh and NDV/Anh-IL-2. HepG2 cells were
infected with virus at MOI of 10 and supernatants were harvested after 24, 48, 72 and
96 h for TCID50 calculation. Results shown represent the mean titer calculated from
two independent experiments.
Fig. 3. Expression of the IL-2 in tumor cell lines after recombinant NDV/Anh-IL-2
infection. HepG2 cell line was infected with NDV/Anh-IL-2 at MOI of 10 for 24, 48
and 72 h. After the infection, the expression of IL-2 was analyzed at those different
time points by ELISA assay.
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Each groups' Samples of mouse tumor was dissected on day 7
after treatment initiation and ﬁxed in 10% formaldehyde phosphate
buffer saline (PBS, pH ¼ 7.4). Then embedded in parafﬁn, sectioned,
stained with hematoxylin/eosin (H&E) (18). Finally were analyzed
microscopically.
2.7. Flow cytometry
Cell suspensions from tumors of sacriﬁced animals were pre-
pared for the presence of CD4þ and CD8þ cells by ﬂuorescence-
activated cell sorting (FACS) analysis. These tumors were
dissected andmanually dissociatedwith scissors. Dissociated tissue
was then collected and incubated at 37 C in RPMI 1640. After
15 min of incubation, 120 ml of 0.5 M EDTA were added to the cell
homogenates and mixed for 5 min. Cells were then ﬁltered using a
cell strainer and stained with CD3þ, CD4þ, and CD8þ (Miltenyi
Biotec) and ﬂow cytometry was done by using Becton Dickinson
FACScan ﬂow cytometer.
2.8. Statistical analysis
Statistical analysis was done using one-way analysis of variance
(ANONA) via SPSS 19.0 software (SPSS, Chicago, IL, USA). Data were
expressed as means ± standard deviation (SD). p < 0.05 was
considered statistically signiﬁcant.
3. Results
3.1. Generation of the recombinant virus NDV/Anh-IL-2
The IL-2 gene ORF was sub-cloned into Bst B I restriction
enzyme site between HN and L genes (Fig. 1). The recombinant
virus was generated by cotransfection of the plasmid coding for the
virus anti-genome, NP, P and L. Cell fusion could be ﬁrst observed at
48 h post transfection, which provided evidence of virus produc-
tion. The viral population was ampliﬁed by inoculation of the cell
cultures into 10-day-old SPF chicken eggs. Allantoic ﬂuid was
collected at 72 h after infection for hemagglutination (HA) and
TCID50 tests. The HA titer reached 1:128 and the TCID50 titer was
2  108 (data not shown).
3.2. Growth characteristics of the recombinant virus
To analyze the growth characteristic of the recombinant virus
NDV/Anh-IL-2 in HepG2 cell line, NDV/Anh strain rescued without
foreign gene was used as a control. HepG2 cells in 24-cell plate
were infected with recombinant virus at 37 C in DMEM with 10%
fetal calf serum (FCS) in 5% CO2 incubator. The supernatant was
harvested at the time 24, 48, 72, 96 h post infections. The TCID50
was calculated by plating 10-fold dilutions of virus supernatant on
DF-1 cells. As shown in (Fig. 2), there was no signiﬁcant difference
between the growth kinetics of the two viruses. The viral yield of
NDV/Anh-IL-2 was slightly lower than that of NDV/Anh.
3.3. Expression of IL-2 by tumor cells infected with NDV/Anh-IL-2
Time course of IL-2 expression in HepG2 cells in response to the
NDV/Anh-IL-2 infection was further investigated. The IL-2 expres-
sion has already shown at 24 h after infection, and it appeared to
reach the maximum at 48 h after infection. At 48 h, the expression
of IL-2 in NDV/Anh-IL-2 is 19.80 ng mL1, NDV/Anh and the mock
cells were 1.37 ng mL1 and 1.20 ng mL1, respectively (p < 0.001).
Afterwards, the concentration of IL-2 appeared almost constantafter 72 h post infection (Fig. 3). This observation can be important
for future applications in clinical, as the foreign gene product
induced by the infection with such recombinant NDV will be
secreted at an early stage in a large quantity.3.4. In vivo treatment of hepatoma with NDV/Anh-IL-2
To evaluate the tumor inhibitory efﬁcacy of NDV/Anh-IL-2
in vivo, 105 H22 cells were s.c. implanted in the right inguen. Tu-
mors developed for 8e10 days, when a touchable tumor was
formed. When tumors volume reached 50e100 mm3, mice were
intratumorally (i.t.) injected with 107 pfu virus every other day for a
total of four times, with PBS and NDV/Anh for control. NDV/Anh-IL-
2 virus exhibited obvious inhibitory efﬁcacy compared with PBS
and NDV/Anh. In 3 out of 6 mice treated with NDV/Anh-IL-2 un-
derwent complete regression in 2e3 weeks after the ﬁrst injection.
Two way ANOVA analyses revealed that there are no interactions
between time and drug treatment. In the fourteenth day, the
average volume of PBS group is 3401.25 mm3, the average of NDV/
Anh treatment group is 1489.97 mm3 and the average of NDV/Anh-
IL-2 is 420.677 mm3. The tumor volume growth of both NDV/Anh
(p < 0.01) and NDV/Anh-IL-2 (p < 0.01) groups exhibited signiﬁcant
suppression when compared with that of PBS group (Fig. 4).
Furthermore, there was signiﬁcant difference in tumor volume
Fig. 4. Hepatoma treated with NDV/Anh-IL-2 can be inhibited in vivo. Six mice per group were evaluated for tumor inhibitory efﬁcacy. Mice were intratumorally injected with
107 pfu virus every other day for a total of four times and with PBS and NDV/Anh for control. Tumor treated with PBS and NDV/Anh had greater burden than the tumor treated with
NDV/Anh-IL-2.
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the fourteenth day (p < 0.05).
More importantly, the three mice which had undergone com-
plete tumor regression exhibited a persistent protection when
rechallenged with 105 H22 cell (the same tumor cells they bore
before, in opposite inguen, 60 days after complete regression).
3.5. Tumors treated with NDV/Anh-IL-2 showed marked T-cell
inﬁltration in vivo
To illustrate the efﬁcacy of IL-2 recombinant in NDV, H&E stain
were used to monitor the lymphocytes inﬁltration in tumor. Tu-
mors from mice treated with PBS, NDV/Anh and NDV/Anh-IL-2, as
previously described, were isolated on day 7 after treatment initi-
ation and stained with H&E. The intense H&E staining pattern of
the NDV/Anh-IL-2 treated animals exhibit an increase in tumor-
inﬁltrating lymphocytes compared with NDV/Anh and PBS con-
trols (Fig. 5A). To speciﬁcally identify cells within the inﬁltrate as
CD4þ and CD8þ T cell, tumors were removed on day 7th and
dissociated into single-cell suspension. These cells were then
stained with anti-CD4þ and anti-CD8þ antibody, then analyzed by
FACS analysis. The rate of CD4þ inﬁltrate Tcell in PBS, NDV/Anh and
NDV/Anh-IL-2 treated group was 0.13%, 2.7% and 4%, respectively.
While the rate of CD8þ inﬁltrate T cell in PBS, NDV/Anh and NDV/
Anh-IL-2 treated group was 0.3%, 2.2%, and 5.7%, respectively. Tu-
mors from the animals treated with NDV/Anh enhanced the inﬁl-
tration rate of both CD4þ and CD8þ T cells obviously; animals
treated with NDV/Anh-IL-2 exhibited a better performance than
NDV/Anh in hepatoma model. There is signiﬁcant difference inCD4þ and CD8þ inﬁltrate T cell number between NDV/Anh group
and NDV/Anh-IL-2 treated group (CD4þ, p < 0.05; CD8þ, p < 0.01)
(Fig. 5B and C).
4. Discussion
Cancer remains a major cause of death in humans. However, the
present therapeutics has not much improved the survival rate of
the patients especially with metastases. In addition to the limita-
tion of resection and side effects of chemo- and radiotherapy, it is
necessary to develop new systematic treatments for cancer therapy
(19e21).
Newcastle disease virus has been applied in clinical studies of
cancer for more than half a century. In the previous studies of
utilizing NDV strains as anticancer agent, encouraging results were
obtained, because of its tumor selectivity (22). Many tumor cell
types exhibit deﬁcient IFN response to viral infection, which is
suitable for oncolytic viruses such as NDV replicating selectively in
tumor cells but not in normal cells (6). Recent study suggested that
the observed oncolytic speciﬁcity of NDV in IFN-competent cancer
cells might be secondary to defects in apoptotic pathways or
overexpression of antiapoptotic proteins, which help to support
productive viral infection and multicycle (23). NDV could specif-
ically replicate up to 10,000 times in tumor cells than in normal
cells causing only mild side effect in humans (3), making it an
attractive candidate of oncolytic agent.
NDV could be classiﬁed as lytic strains and non-lytic strains,
based on the different oncolytic capabilities. Lytic strain usually
includes 73-T (24), MTH-68/H (25) and PV 701 (26) can kill the
Fig. 5. Representative sections of H&E-stained mouse tumors. A. Mouse tumors were dissected on day 7 after treatment initiation. Intense inﬁltration was observed in the NDV/
Anh-IL-2 treated tumors compared with both PBS and NDV/Anh treated tumors. B and C, recombinant viruses increased CD4þ and CD8þ T cells inﬁltration. The tumors from the
sacriﬁced mice dissociated into single-cell suspension. The tumor cells were analyzed for the inﬁltration of CD4þ and CD8þ by FACS (n ¼ 3 mice per group).
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cells fusion to form syncytia (27). Non-lytic strains (e.g., Ulster
strain) (27,28) can gradually induce tumor regression by affecting
the metabolism of the host cell and enhance the immune response
in vivo (27). But different NDV strains have different effects on tu-
mor therapy, for instance, NDV classic 73-T strain, which has an
outstanding performance in malignant melanoma therapy, could
not damage daudi cells (29,30). So it is signiﬁcant to discover new
effective NDV strain as a vaccine vector for tumor therapy. Our
previous study proved that NDV Anhinga strain could be classiﬁed
as a lytic strain which has an effective oncolytic role on hepatoma
(15). But the NDV Anhinga strain has never been used as a vaccine
vector for expressing tumor therapeutic factors before. In this
study, we proved that NDV Anhinga strain could successfully ex-
press tumor therapeutic factor to enhance the antitumor capability.
Numerous reports had shown that NDV is also an immunosti-
mulatory agent, as it can induce antitumor activities of a variety of
effector cells, including NK cells, macrophages, and CTL (11,31e33).
The immune system could respond to virus-infected cancer cells (or
fragments of cancer cells), then better recognition of tumor-speciﬁc
antigens may occur, and an increased ability to kill uninfected
cancer cells may be acquired (9). The immune systemwould use the
same approaches to kill uninfected cancer cells that it uses to kill
virus-infected cells. From the H&E-stained sections, the NDV
Anhinga strain treated group showed an enhancement of
lymphocyte inﬁltration compared to the PBS group. We can
demonstrate that NDV Anhinga strain could boost the immune
system and increase the lymphocyte inﬁltration.
For over 20 years, IL-2 has been widely used in clinical tumor
therapy and received a wonderful result. It has been reported that52 pancreatic carcinoma stage G3 cancer patients were treated
with NDV vaccine adding IL-2, followed up experiment demon-
strated that 22% were survived for more than 5 years free of tumor,
33% alive for 24, 21 and 18 months separately, while 45% survived
for 9e10 months (34). Previous study demonstrated that NDV La
Sota strain which is a non-lytic strain recombinanted with IL-2 has
a great result in hepatic carcinoma and malignant melanoma
therapy (35), which could become a potential candidate for tumor
therapy (5).
Adam Vigil et al (4) reported that lytic strain has a better tumor
killing capability than non-lytic strain. They proved that lytic strain
virus could not only kill the tumor directly, but could also elicit a
potent immunological memory in therapeutic process, which has
been proved by non-lytic strain virus. They used NDV Hitchner B1
(B1 strain) lentogenic strain as a backbone to construct recombi-
nant virus NDV/F3aawhich contain a multibasic cleavage site in the
F protein of the virus. Because highly virulent strain of NDV in birds
are classiﬁed as velogenic, intermediate strains as mesogenic, and
nonvirulent strains as lentogenic based on the mean death time in
chicken eggs (36). The precursor F0 protein is only fusogenic after it
is cleaved into F1 and F2 polypeptides. The different F protein
cleavage sequences of NDV strains are recognized by distinct
cellular protease (37). The F0 proteins from lentogenic viruses are
only cleaved by trypsin-like proteases found in the respiratory and
intestinal tracts of birds, whereas the F proteins of velogenic strains
can be cleaved by a broad range of protease found in awide range of
tissue.
So after the modiﬁcation of the F protein, the NDV/F3aa strain
has an increased antitumor efﬁcacy compared with the wild-type
parental NDV (B1 strain) by increasing the fusion capability of
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of NDV is directly related with its virulence. Therefore, we ﬁrstly
used the lytic and mesogenic strain Anhinga as backbone to
construct the recombinant virus which could secrete human IL-2.
From the H&E stain and FACS results, NDV/Anh-IL-2 treated ani-
mals demonstrated an obvious raise in tumor-inﬁltrating lympho-
cytes number compared with NDV/Anh and PBS controls. The
results of CD8þ T cell elevation demonstrate that IL-2 had a syn-
ergistic action with NDV Anhinga strain. Importantly, the results of
CD4þ T cell elevation in the tumor could explain that all of the mice
which underwent complete regressions of tumors exhibited a long-
lasting protection from tumor. 60 days post-treatment, mice which
were completely cured by previous therapy were also well pro-
tected when rechallenged with the same tumor cell. All the facts
concluded that the increased number of CD4þ and CD8þ T cells in
the tumor lead to the enhanced tumor reduction and long lasting
tumor memory. We also observed that animals experienced with
multiple injections didn't show any behavioral changes nor any
malformations or carcinogenesis signs in their descendants.5. Conclusion
In our previous study, we have proved the antitumor effect of
NDV Anhinga strain in hepatocarcinoma and classiﬁed the strain as
a lytic strain. In this study, we constructed NDV Anhinga strain
recombinant with IL-2 (NDV/Anh-IL-2), which exerts an obvious
result in hepatocellular carcinoma treatment in vivo. We demon-
strated that NDV Anhinga strain could not only kill tumor directly
but also could elicit immune reaction and a potent immunological
memory in vivo which could become an effectual vector for tumor
treatment; Based on the result of expression of the cytokine human
IL-2, NDV/Anh-IL-2 enhanced the antitumor properties by
increasing inﬁltration of lymphocyte in vivo, which could become a
potent candidate for clinical carcinoma therapy especially for
hepatocarcinoma. Further studies remain necessary to investigate
more suitable tumor lineages for Anhinga strain for clinical
application.Conﬂict of interest
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